Document Detail


Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs.
MedLine Citation:
PMID:  9357967     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the effect of recombinant canine stem cell factor (rcSCF) on hematopoietic recovery, incidence of graft failure, graft-vs.-host disease (GVHD), and survival after marrow transplantation from dog leukocyte antigen (DLA)-identical canine littermates. Ten animals received 100 microg rcSCF/kg/day b.i.d. by subcutaneous injection on days 1 through 10 after 920 cGy total body irradiation and transplantation of a mean of 3.7x10(8) marrow cells/kg body weight. None of the dogs received GVHD prophylaxis. All animals showed hematopoietic engraftment. The median number of days to achieve 1000 neutrophils/mm3 was 9; 100 monocytes/mm3 were reached after 15 days, 500 lymphocytes/mm3 after 21 days, and 20,000 platelets/mm3 after 16 days. One animal developed GVHD involving skin, gut, and liver and died of bacterial pneumonia 21 days after transplantation. The remaining nine dogs were observed for a median of 37 days (range 29-84 days) posttransplantation until they were killed. Facial edema was seen in three dogs during the first 2-3 days of rcSCF administration. These results show that within the limits of this study it appears to be safe to administer SCF after DLA-identical littermate marrow transplants in dogs. Comparison with previously published data in the same model showed that neutrophil and monocyte recovery was significantly faster in dogs receiving SCF treatment compared with dogs without growth factor treatment (recovery to achieve 1000 neutrophils/mm3: median 9 days vs. 13 days, p = 0.002; recovery to 100 monocytes/mm3: median 15 days vs. 105 days, p = 0.0002). Otherwise, no significant differences were seen. Results obtained with SCF treatment were similar to those previously obtained in the same model with recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment except that recovery of lymphocytes to 500/mm3 appeared to be more rapid in G-CSF-treated dogs (median 15 days vs. 21 days, p = 0.03).
Authors:
F G Schuening; C von Kalle; H P Kiem; F R Appelbaum; H J Deeg; M Pepe; T Gooley; T C Graham; R C Hackman; R Storb
Related Documents :
2616667 - Hypotensive activity of 8,24-euphadien-3 beta-ol (euphol).
1001337 - A study of the verapamil-induced changes in conductivity and refractoriness and monopha...
22089267 - High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a random...
20579327 - A phase ii study to evaluate the toxicity and efficacy of alternating ccnu and high-dos...
19028617 - Antibacterial activity of cefditoren against major community-acquired respiratory patho...
2892437 - Rapid administration of a narcotic and neuromuscular blocker: a hemodynamic comparison ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Experimental hematology     Volume:  25     ISSN:  0301-472X     ISO Abbreviation:  Exp. Hematol.     Publication Date:  1997 Nov 
Date Detail:
Created Date:  1997-11-20     Completed Date:  1997-11-20     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0402313     Medline TA:  Exp Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1240-5     Citation Subset:  IM    
Affiliation:
The University of Wisconsin, Madison, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bone Marrow Transplantation / immunology,  veterinary*
Dogs
Female
Graft Survival
Graft vs Host Disease / etiology
Granulocyte Colony-Stimulating Factor / pharmacology
Hematopoiesis / drug effects*
Histocompatibility
Male
Recombinant Proteins / pharmacology
Stem Cell Factor / pharmacology*
Time Factors
Grant Support
ID/Acronym/Agency:
CA15704/CA/NCI NIH HHS; CA18221/CA/NCI NIH HHS; DK42716/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 0/Stem Cell Factor; 143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relative population sizes of megakaryocytic cells in mouse bone marrow as determined by mpl liga...
Next Document:  Human T lymphotropic virus-type I Tax induction of CD21/Epstein-Barr virus receptor expression on T ...